RCUS LONGI expect a first touch bounce of the montly $11.66 level. I pulled this fib off the move to the all time high and I will be targeting the two boxes above. My fibs are pulled from the move to the all time high.
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−3.10 USD
−283.00 M USD
258.00 M USD
64.90 M
About Arcus Biosciences, Inc.
Sector
Industry
CEO
Terry J. Rosen
Website
Headquarters
Hayward
Founded
2015
FIGI
BBG00DQD26W3
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of immunotherapies. It competes in the segments of the pharmaceutical, biotechnology, and other related markets that develop immunotherapies for the treatment of cancer. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is headquartered in Hayward, CA.
RCUS 1M 7.4% Increase and then 77% DeclineArcus Biosciences, Inc. engages in the development and commercialization of immunotherapies. It competes in the segments of the pharmaceutical, biotechnology and other related markets that develop immunotherapies for the treatment of cancer. The company was founded by Terry J. Rosen and Juan Carlos
RCUS:Bullish continuation!Arcus Biosciences
Short Term - We look to Buy at 27.75 (stop at 25.94)
Daily signals are bullish. A weaker opening is expected to challenge bullish resolve. Prices expected to stall near trend line support. Dip buying offers good risk/reward. Further upside is expected although we prefer to bu
RCUSThis BioScience company has many products in the testing phases through to the FDA approvals. The stock has also missed earnings multiple times in the past and that is the majority reason why it is currently failing. keep a watch on this to see if it hits new lows and can be a great buy if one of th
RCUS - Long Setup Phase 2 data expected 2Q 2021 based on BioPharm catalyst website. Gilead have been buying as well as another insider. Watch for a break of 36.13. Stop signal 26.44. Momentum target.
Interesting Oppty...Analyst targets are pretty high and carries Zacs #1 rating. A breakout will lead it higher.
finance.yahoo.com
RCUS 50+% Potential Gains Friday, January 15-17RCUS releases phase one clinical trial data for a drug they are developing to treat pancreatic cancer on Friday, January 15-17. Look to buy about a week in advance.
RCUS 50% retrace/50/200 EMA supportRCUS has reacted higher after bouncing from a confluence of support:
1) 200 EMA
2) 50% retracement
3) VWAP from all time low
*You can see how the 200 EMA and VWAP from all time low previously acted as the floor back in March
-Now supported strongly by 50 EMA, RCUS closed above the 50 EMA every day
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Related stocks
Frequently Asked Questions
The current price of RCUS is 8.18 USD — it has decreased by −4.24% in the past 24 hours. Watch Arcus Biosciences, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NYSE exchange Arcus Biosciences, Inc. stocks are traded under the ticker RCUS.
RCUS stock has fallen by −9.06% compared to the previous week, the month change is a −29.85% fall, over the last year Arcus Biosciences, Inc. has showed a −55.30% decrease.
We've gathered analysts' opinions on Arcus Biosciences, Inc. future price: according to them, RCUS price has a max estimate of 46.00 USD and a min estimate of 17.00 USD. Watch RCUS chart and read a more detailed Arcus Biosciences, Inc. stock forecast: see what analysts think of Arcus Biosciences, Inc. and suggest that you do with its stocks.
RCUS reached its all-time high on Nov 22, 2021 with the price of 49.10 USD, and its all-time low was 6.30 USD and was reached on Aug 5, 2019. View more price dynamics on RCUS chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
RCUS stock is 5.54% volatile and has beta coefficient of 2.50. Track Arcus Biosciences, Inc. stock price on the chart and check out the list of the most volatile stocks — is Arcus Biosciences, Inc. there?
Today Arcus Biosciences, Inc. has the market capitalization of 898.59 M, it has decreased by −7.58% over the last week.
Yes, you can track Arcus Biosciences, Inc. financials in yearly and quarterly reports right on TradingView.
Arcus Biosciences, Inc. is going to release the next earnings report on May 13, 2025. Keep track of upcoming events with our Earnings Calendar.
RCUS earnings for the last quarter are −1.03 USD per share, whereas the estimation was −1.25 USD resulting in a 17.52% surprise. The estimated earnings for the next quarter are −1.02 USD per share. See more details about Arcus Biosciences, Inc. earnings.
Arcus Biosciences, Inc. revenue for the last quarter amounts to 36.00 M USD, despite the estimated figure of 29.33 M USD. In the next quarter, revenue is expected to reach 38.61 M USD.
RCUS net income for the last quarter is −94.00 M USD, while the quarter before that showed −92.00 M USD of net income which accounts for −2.17% change. Track more Arcus Biosciences, Inc. financial stats to get the full picture.
No, RCUS doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Mar 28, 2025, the company has 627 employees. See our rating of the largest employees — is Arcus Biosciences, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Arcus Biosciences, Inc. EBITDA is −300.00 M USD, and current EBITDA margin is −116.28%. See more stats in Arcus Biosciences, Inc. financial statements.
Like other stocks, RCUS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Arcus Biosciences, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Arcus Biosciences, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Arcus Biosciences, Inc. stock shows the strong sell signal. See more of Arcus Biosciences, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.